Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
12/06/202313h00Business WireAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®NYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/202318h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)
NYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/202316h39Dow Jones NewsNY AG Lands Final Approval for $17.3 Billion Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202315h27Dow Jones NewsTeva Pharma Reaches Opioid Settlement With Nevada, the Final State to Resolve ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202314h31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202314h30Business WireTeva Concludes Nationwide Opioids Settlement AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
06/06/202314h00Business WirePhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma ManagementNYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/202322h30Business WireTeva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h29Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/05/202317h00Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
18/05/202314h30Business WireTeva Launches New “Pivot to Growth” StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202314h00Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202313h00Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202313h00Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of ScheduleNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202314h30Business WireU.S. Mental Health Access Program Expands Medicine Donation to Seven New StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva et MedinCell annoncent l'approbation par la FDA américaine de UZEDY™ (risperidone), un antipsychotique sous forme de suspension injectable sous-cutanée à libération prolongée pour le traitement de la schizophrénie chez l'adulteNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/202314h35Business WireTeva to Launch New Growth Strategy at Investor DayNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202322h18Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202322h15Business WireTeva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202320h28Dow Jones NewsTeva Shares Drop 11% After Alvotech Gets FDA Complete Response LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202302h53Business WireComplete Response Letter Received for AVT02 Biologics License ApplicationNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202314h00Business WireTeva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
27/03/202314h00Business WireTeva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health SystemNYSE:TEVATeva Pharmaceutical Industries Ltd
13/03/202314h33Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202314h00Business WireTeva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202322h00Business WireTeva to Present at the Barclays Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA